recent pharma news

Sep 19, 2019

FUJIFILM Corporation has signed an exclusive licensing agreement with an Australian bio-venture Cynata Therapeutics Limited for CYP-001. Under the agreement, FUJIFILM will gain rights to develop, manufacture and market a drug for the treatment of graft-versus-host disease (GvHD). CYP-001 is a Cynata’s lead cand...

Sep 17, 2019

AlivaMab Discovery Services (ADS) has announced an antibody discovery agreement against multiple targets with Janssen Research & Developments. AlivaMab, a pharmaceutical providing fully human therapeutic antibody discovery services, will render its therapeutic antibody candidates, its clinical expertise and...

Sep 12, 2019

Mallinckrodt has announced to sell its Canadian drug manufacturing BioVectra Inc. to a Miami-based private equity firm, an affiliate of H.I.G. Capital for approximately USD 250 Million. The agreement included a fixed amount of USD 175 Million, with an upfront amount of USD 135 Million, a long term payment of US...

Sep 10, 2019

Daiichi Sankyo announced the submission of a New Drug Application (NDA) of DS-8201 to Japan's Ministry of Health, Labour and Welfare (MHLW). DS-8201 [fam-] trastuzumab deruxtecan), is an investigational antibody-drug conjugate (ADC) designed to deliver cytotoxic chemotherapy to cancer cells via a human epiderma...

Sep 03, 2019

Helsinn Group grants exclusive licensing rights to Blanver and Varifarma for its leading drug Pracinostat in South America. Helsinn is a Swiss biopharmaceutical company committed to producing the best solutions aimed at improving the quality of life for people with cancer. Under the terms of the agreements, ...

Oct 03, 2017

Strategic Immunology Alliance partners Nimbus Therapeutics and Celgene to develop therapies for Autoimmune Disorders A biotechnology company involved in the development of drugs and therapies through computational expertise announced on October 3 that they are entering into a long-term strategic alliance with Celgen...

Sep 28, 2017

Another flop for Alzeimer’s as Late Stage drug of AxovantSciences fails in trial Axovant Sciences has reported the failure of their late-stage trial involving the testing of its pill Intepirdinecould not suppress Alzheimer's symptoms in participants of the trail. The news had plunged the Wall Street into another wav...